Skip to main content

IP Update: Recent Patents Awarded to Alnylam, Merck, Alcon

Premium

Title: Hepatitis C dsRNA Effector Molecules, Expression Constructs, Compositions, and Methods of Use

Patent Number: 8,614,198

Filed: June 28, 2008

Lead Inventor: Daniel McCallus, Alnylam Pharmaceuticals


Title: Double-stranded RNA Director to CASP2 and Methods of Use Thereof

Patent Number: 8,614,309

Filed: Sept. 4, 2008

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals


Title: Devices, Systems, and Methods for Improving Memory and/or Cognitive Function through Brain Delivery of siRNA

Patent Number: 8,618,069

Filed: Oct. 8, 2009

Lead Inventor: William Kaemmerer, Medtronic


Title: RNA Interference-mediated Inhibition of Gene Expression using Chemically Modified Short Interfering Nucleic Acid

Patent Number: 8,618,277

Filed: May 25, 2012

Lead Inventor: Leonid Beigelman, Merck


Title: RNAi-mediated Inhibition of Histamine Receptor H1-related Conditions

Patent Number: 8,618,278

Filed: June 11, 2012

Lead Inventor: John Yanni, Alcon

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.